Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept-Reference-Cited by-同舟云学术

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept

Published:2016-02-01 Issue:1 Volume:2 Page:
ISSN:2056-9920
Container-title:International Journal of Retina and Vitreous
language:en
Short-container-title:Int J Retin Vitr

Author:

de Oliveira Dias João Rafael^ORCID,de Andrade Gabriel Costa,Novais Eduardo Amorim,Farah Michel Eid,Rodrigues Eduardo Büchele

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

http://link.springer.com/content/pdf/10.1186/s40942-016-0026-y

Reference38 articles.

1. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25.

2. Zachary I. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules. IDrugs. 2003;6:224–31.

3. Konerding MA. Ocular angiogenesis: translating preclinical indications to successful clinical development. Expert Opin Ther Targets. 2004;8(3):255–8.

4. Glaser BM, D’Amore PA, Lutty GA, Fenselau AH, Michels RG, Patz A. Chemical mediators of intraocular neovascularization. Trans Ophthalmol Soc. 1980;100:369–73.

5. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006;142:660–8.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis;Frontiers in Pharmacology;2024-01-04

2. A bioengineered anti‐VEGF protein with high affinity and high concentration for intravitreal treatment of wet age‐related macular degeneration;Bioengineering & Translational Medicine;2023-12-19

3. scAAV2-Mediated Expression of Thioredoxin 2 and C3 Transferase Prevents Retinal Ganglion Cell Death and Lowers Intraocular Pressure in a Mouse Model of Glaucoma;International Journal of Molecular Sciences;2023-11-13

4. Applications of nanomaterials in anti‐VEGF treatment for ophthalmic diseases;Journal of Biomedical Materials Research Part A;2023-10-18

5. An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye;ACS Omega;2023-09-22